Pharmaceutical industry – Page 44
-
Business
Novo Nordisk quits inflammation R&D and cuts jobs
Firm will return to primary focus on diabetes and obesity
-
Business
Exelexis slashes workforce by 70%
Poor clinical trial performance pushes company into cost-cutting drive
-
BusinessRoche to buy InterMune for respiratory boost
$8.3bn deal gives Roche a leading position in pulmonary fibrosis
-
Business
Clinical collaborations drive cancer immunotherapy
Companies race to pair up chemotherapy drugs with immune system-boosting antibodies to greatest effect in trials
-
OpinionDeath of a reagent
Fashion and progress combine to mean some reactions and reagents persist, while others fall by the wayside, says Derek Lowe
-
Business
Sanofi snaps up inhaled insulin licence
Deal gives Mannkind access to global manufacturing and distribution for recently-approved Afrezza
-
Business
Single shot antibiotic approved for skin infections
Third drug in three months approved under US antimicrobials incentive scheme
-
Business
GSK’s China troubles continue
Analysts say stings will only drive corruption into less visible channels
-
BusinessPrice caps provoke lawsuits from Indian pharma industry
New government controls on cardiovascular and diabetes drugs challenged by industry lobby groups
-
Business
Amgen to shed 2400-2900 jobs
Restructuring will see three sites close as company comes under pressure to streamline R&D, despite successes
-
Business
AstraZeneca stocks respiratory and cancer pipelines
A $2bn deal with Almirall and a raft of acquisitions and partnership deals bulk up two focus areas for the company
-
Business
Reckitt Benckiser to spin out US pharma arm
Declining heroin addiction treatment sales prompt divestment as company focuses on over-the-counter and consumer products
-
BusinessTakeover battle pushes Allergan to cut R&D jobs
Besieged by serially acquisitive Valeant, the Botox maker will lay off 1500 staff to propel earnings growth
-
BusinessPharma firms rush to escape US tax shackles
AbbVie–Shire and Mylan–Abbott mergers both allow US firms to escape to lower-tax European countries
-
Business
China struggles to speed up drug reviews
Regulator considers outsourcing reviews, and creates a fast-track scheme for priority generics
-
Business
First of a new breed of anticancer antibodies approved in Japan
Ono claims Opdivo is the first anti-PD1 treatment in the world
-
BusinessEMA wrangles restrain trial data progress
Attempts to balance industry and research interests on transparency draw suggestions of improper collusion
-
Business
Genentech to buy breast cancer specialist Seragon
$1.7bn deal for hormone receptor-destroying drug pipeline
-
Business
Inhaled insulin approved in US
European committee recommends approval for generic long-acting insulin
-
Business
Affymax folds after drug withdrawal
Unexplained allergic reactions to anaemia drug prompt firm to dissolve